Management of Hiv

download Management of Hiv

of 14

Transcript of Management of Hiv

  • 8/3/2019 Management of Hiv

    1/14

    MANAGEMENT OF HIV

  • 8/3/2019 Management of Hiv

    2/14

    Diagnosis of HIV infection in children

    HIV serological assays:

    18 months of age

    used as a diagnostic assay

    sensitivity of 99%

    specificity of 98%

  • 8/3/2019 Management of Hiv

    3/14

    HIV virological assays

    used to diagnose HIV infection in infants andchildren less than 18 months of age.

    HIV DNA on whole blood specimen or dried bloodspots (DBS)

    HIV RNA on plasma or DBS

    ultrasensitive p24 antigen (Up24 Ag) on plasma or

    DBS

    sensitivity of 95%

    specificity of 98%

  • 8/3/2019 Management of Hiv

    4/14

    It is strongly recommended that well, HIV-exposedinfants undergo HIV serological testing at around 9

    months of age .Those who have reactive serologicalassays at 9 months should have a virological test to

    identify infected infants who need ART.

    Infants with signs or symptoms suggestive of HIVinfection undergo HIV serological testing and, if

    positive (reactive), virological testing.

  • 8/3/2019 Management of Hiv

    5/14

    TREATMENT

  • 8/3/2019 Management of Hiv

    6/14

    ANTIRETROVIRAL THERAPY IN PREGNANCY

    1. ARV PROPHYLAXIS: A) MATERNAL AZT REGIMEN

    B) TRIPLE ARV PROPHYLAXIS REGIMEN

    from 14 wks gestation until 1 week after all

    exposure to breastmilk has ended

    2. ART : STAGE 3, 4 OR CD4 COUNT < 350cells/mm3

    Continue thereafter

  • 8/3/2019 Management of Hiv

    7/14

    Recommendations for initiating ART in

    infants and children

  • 8/3/2019 Management of Hiv

    8/14

    Recommendations for initiating ART in HIV-

    infected infants and children according to clinical

    stage and immunological markers

    a

    Stabilize any opportunistic infection (OI) before initiating ART.

    bBaseline CD4 is useful for monitoring ART even if it is notrequired to initiate ART.

  • 8/3/2019 Management of Hiv

    9/14

    ARV DRUGS are broadly classified by the

    phase of the retrovirus life-cycle that the

    drug inhibits: 1. Non-nucleoside reverse transcriptase inhibitors

    (NNRTI): Efavirenz ,Nevirapine

    2. Nucleoside reverse transcriptase inhibitors(NRTI):Zidovudine, Didanosine ,Zalcitabine ,Stavudine ,Lamivudine

    3. Protease inhibitors : Ritonavir, indinavir 4. Entry inhibitors :Enfuvirtide

    5. CCR5 receptor antagonists

    6. Integrase inhibitors: Raltegravir

    http://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Protease_inhibitor_(pharmacology)http://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Ritonavirhttp://en.wikipedia.org/wiki/Indinavirhttp://en.wikipedia.org/wiki/Entry_inhibitorshttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Enfuvirtidehttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Discovery_and_development_of_CCR5_receptor_antagonistshttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Integrase_inhibitorhttp://en.wikipedia.org/wiki/Discovery_and_development_of_CCR5_receptor_antagonistshttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Discovery_and_development_of_CCR5_receptor_antagonistshttp://en.wikipedia.org/wiki/Discovery_and_development_of_CCR5_receptor_antagonistshttp://en.wikipedia.org/wiki/Integrase_inhibitorhttp://en.wikipedia.org/wiki/Integrase_inhibitorhttp://en.wikipedia.org/wiki/Integrase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Discovery_and_development_of_CCR5_receptor_antagonistshttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Enfuvirtidehttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Entry_inhibitorshttp://en.wikipedia.org/wiki/Indinavirhttp://en.wikipedia.org/wiki/Ritonavirhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Protease_inhibitor_(pharmacology)http://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitorhttp://en.wikipedia.org/wiki/Reverse_transcriptase_inhibitor
  • 8/3/2019 Management of Hiv

    10/14

    RECOMMENDED FIRST-LINE ARV

    REGIMENS FOR INFANTS AND CHILDREN

    < 24 months

    1. Not exposed to ARVs: ART with nevirapine(NVP) + 2 nucleoside reverse transcriptase inhibitors

    (NRTIs).

    2. Exposed to maternal or infant NVP or otherNNRTIs used for maternal treatment: ART with

    lopinavir/ritonavir (LPV/r) + 2 NRTIs.

  • 8/3/2019 Management of Hiv

    11/14

    For children more than 24 months and less than 3years of age : ART with NVP + 2 NRTIs.

    For children 3 years of age and above: ART with anNVP or efavirenz (EFV)-containing regimen + 2NRTIs.

  • 8/3/2019 Management of Hiv

    12/14

    ARV DRUG TOXICITY

    Toxicity event Responsible ARV

    Severe anemia or neutropeniaLactic acidosis

    Severe gastrointestinal intolerance

    ZIDOVUDINE

    Lactic acidosis

    Peripheral neuropathyPancreatitis

    STAVUDINE

    Acute symptomatic hepatitisHypersensitivity reaction

    NEVIRAPINE

    Persistent and severe central nervoussystem toxicityPotential teratogenicity

    EFAVIRENZ

  • 8/3/2019 Management of Hiv

    13/14

    After failure on a first-line NNRTI-based regimen, aboosted PI plus 2 NRTIs are recommended for

    second-line ART.

  • 8/3/2019 Management of Hiv

    14/14

    THANK YOU